These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11776376)

  • 1. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
    Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
    Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
    Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
    Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
    Shinoda M; Kudo T; Suzuki M; Katayose Y; Sakurai N; Saeki H; Kodama H; Fukuhara K; Imai K; Hinoda Y; Matsuno S
    Cancer Res; 1998 Jul; 58(13):2838-43. PubMed ID: 9661899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
    Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
    Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
    Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
    Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
    Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.
    Sakurai N; Kudo T; Suzuki M; Tsumoto K; Takemura S; Kodama H; Ebara S; Teramae A; Katayose Y; Shinoda M; Kurokawa T; Hinoda Y; Imai K; Matsuno S; Kumagai I
    Biochem Biophys Res Commun; 1999 Mar; 256(1):223-30. PubMed ID: 10066451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
    Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
    Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
    Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
    Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
    Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model.
    Boehncke WH; Hardt-Weinelt K; Nilsson H; Wolter M; Dohlsten M; Ochsendorf FR; Kaufmann R; Antonsson P
    J Invest Dermatol; 2001 Apr; 116(4):596-601. PubMed ID: 11286628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered superantigens as tolerable antitumor agents.
    Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
    Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
    Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
    Newton DW; Dohlsten M; Olsson C; Segrén S; Lundin KE; Lando PA; Kalland T; Kotb M
    J Immunol; 1996 Nov; 157(9):3988-94. PubMed ID: 8892632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo anti-MUC1
    Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
    Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.